Lilly Orgorglipron
Orforglipron is a novel, oral, non-peptide GLP‑1 receptor agonist, and the ACHIEVE‑1 Phase III data demonstrated efficacy and tolerability comparable to existing injectables
Oral Presentation – Lilly will feature its oral GLP‑1 candidate, orforglipron, with topline results from its Phase III ACHIEVE‑1 trial showing positive safety, glycemic control, and weight loss (~8 % at 40 weeks). This will be presented in a symposium format.
TBD (scheduled during ADA thematic symposium on obesity/GLP‑1; check the official ADA online planner for exact timing)
Lilly Eloralintide
Eloralintide, also known as LY-3841136, is an experimental weight-loss drug. It is being investigated as a potential treatment for obesity and type 2 diabetes.
Mechanism of Action:
Eloralintide is an amylin receptor agonist. It mimics the action of amylin, a hormone produced by the pancreas that is co-secreted with insulin. Amylin helps regulate blood sugar levels by slowing gastric emptying (slowing the rate at which food leaves the stomach) and suppressing appetite, making you feel full for a longer time.
Poster Presentation – Title: Experimental obesity drug eloralintide showed ~11.5 % weight loss at 12 weeks in early-stage trial
Sunday 6/22, 12:30–13:30 CT
🎯Clinical Trial Updates
Lilly SURMOUNT 1
Title: Association of Tirzepatide with Kidney Parameters in People with Obesity and Prediabetes from SURMOUNT‑1 over 176 Weeks
🕒 Friday, June 20, 5:30–6:30 p.m. CDT
Location: Ballroom W185 A–D
Presenter: Dr. Hiddo L. Heerspink, PhD (Lilly)
Title: Sustained Weight Reduction by Thresholds in Adults with Obesity and Prediabetes Treated with Tirzepatide over 176 Weeks (SURMOUNT‑1)
🕒 Friday, June 20, 5:30–6:30 p.m. CDT
Location: Ballroom W196 BC
Presenter: Dr. Jamy D. Ard, MD (Lilly)
🔄 SURMOUNT-5 (Head-to-head vs semaglutide)
Title: SURMOUNT‑5 Tirzepatide vs. Semaglutide for Obesity—Rapid Responders and Associated Weight Reduction and Safety
🕓 Saturday, June 21, 4:30–6:00 p.m. CDT
Location: Ballroom W181 A–C
Presenter: Dr. Louis Aronne, MD, FACP, DABOM
Takeaways
SURMOUNT‑1 findings continue to show that 176 weeks of tirzepatide therapy (up to 15 mg weekly) yields exceptionally sustained weight loss and improvements in kidney-related outcomes in adults with obesity and prediabetes.
SURMOUNT‑5 is a high-impact head‑to‑head trial comparing tirzepatide with semaglutide (Wegovy®). Results demonstrate significantly greater weight reduction (~20 % with tirzepatide vs. ~14 % with semaglutide), with Dr. Aronne presenting responder dynamics and safety data.